Omnicell’s (OMCL) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Omnicell (NASDAQ:OMCL) in a research report sent to investors on Monday,Benzinga reports. Piper Sandler currently has a $45.00 price target on the stock, down from their prior price target of $55.00.

A number of other equities research analysts have also recently commented on OMCL. Craig Hallum reiterated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Zacks Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

Shares of OMCL stock opened at $37.17 on Monday. The business’s fifty day simple moving average is $41.58 and its 200-day simple moving average is $40.73. The company has a market cap of $1.69 billion, a PE ratio of 44.25, a PEG ratio of 1.01 and a beta of 0.98. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell has a 12-month low of $29.06 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. During the same quarter in the prior year, the business posted $0.45 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts expect that Omnicell will post 1.31 earnings per share for the current fiscal year.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.

Hedge Funds Weigh In On Omnicell

A number of institutional investors have recently bought and sold shares of OMCL. Raymond James Financial Inc. acquired a new stake in Omnicell during the 2nd quarter valued at approximately $26,000. Versant Capital Management Inc raised its holdings in shares of Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the last quarter. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Omnicell during the fourth quarter valued at $58,000. Finally, Parkside Financial Bank & Trust boosted its holdings in Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after purchasing an additional 1,264 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.